AZD9272 and AZD2066: Selective and Highly Central Nervous System Penetrant mGluR5 Antagonists Characterized by Their Discriminative Effects-Reference-Cited by-同舟云学术

AZD9272 and AZD2066: Selective and Highly Central Nervous System Penetrant mGluR5 Antagonists Characterized by Their Discriminative Effects

Published:2014-05-29 Issue:2 Volume:350 Page:212-222
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Swedberg Michael D. B.^ORCID,Raboisson Patrick

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference60 articles.

1. Palladium mediated 11C-cyanation and characterization in the non-human primate brain of the novel mGluR5 radioligand [11C]AZD9272

2. Phencyclidine (PCP): A Review and Perspectives

3. Lorazepam and pentobarbital drug discrimination in baboons: cross-drug generalization and interaction with Ro 15-1788;Ator;J Pharmacol Exp Ther,1983

4. Phencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug;Bey;Cal J Emerg Med,2007

5. Central stimulants as discriminative stimuli

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. International Union of Basic and Clinical Pharmacology. CXI. Pharmacology, Signaling, and Physiology of Metabotropic Glutamate Receptors;Pharmacological Reviews;2020-12-23

2. Detailed In Vitro Pharmacological Characterization of Clinically Tested Negative Allosteric Modulators of the Metabotropic Glutamate Receptor 5;Molecular Pharmacology;2020-05-01

3. Location and Cell-Type-Specific Bias of Metabotropic Glutamate Receptor, mGlu5, Negative Allosteric Modulators;ACS Chemical Neuroscience;2019-10-14

4. Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology;Neuropharmacology;2019-05

5. Targeting metabotropic glutamate receptors in the treatment of epilepsy: rationale and current status;Expert Opinion on Therapeutic Targets;2019-03-21